Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05190848 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Correlation of Microbiome and Metabonomics With IgA Nephropathy

StatusRecruiting
PhaseNot specified
Started2020-05-01
View on ClinicalTrials.gov ↗
IgAN is the most prevalent primary glomerulonephritis in China, is characterized by the deposition of IgA1 (particularly, galactose-deficient IgA1) in the glomerular mesangium. Galactosedeficient IgA1, supposed to be produced by Peyer patches in the mucosa-associated lymphoid tissue (MALT), is triggered by exposure to commensal or pathogenic bacteria, involved in the initial step in the pathogenesis of IgAN. Similar to intestinal flora, a disruption in oral flora is closely associated with the occurrence of many malignant tumors and autoimmune diseases. The relationship between oral and throat microflora and the occurrence of IgAN is unclear at present. The aim of the present study was to develop a preliminary model based on mucosa -specific microbes and clinical indicators to facilitate the early diagnosis of IgAN and obtain insights into its treatment.

Amendment history 1 change detected by DataLookout

2026-09-15
minor
Completion pushed: 2025-12-01 → 2027-12-31
Trial Details
NCT Number NCT05190848
Lead Sponsor Guangdong Provincial People's Hospital
Conditions IgA Nephropathy
Enrollment 600 participants
Start Date 2020-05-01
Primary Completion 2024-12-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-14